2025
Advancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance
Jiang W, Gan D, Johnson M, Latich I, Lee F. Advancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance. EngMedicine 2025, 2: 100051. DOI: 10.1016/j.engmed.2024.100051.Peer-Reviewed Original ResearchPainful sacral metastasesIntra-operative image guidanceSacral metastasesImage guidancePreoperative baselineFollow-upPercutaneous interventionFunction scoresLong-term follow-upRisk of cement leakageO-arm navigationImprovement of painRetrospective cohort reviewImage guidance techniquesAverage follow-upInterventional oncology proceduresIntra-operative imaging techniquesO-armPercutaneous ablationSingle-institutionCohort reviewPrimary cancerClinical improvementMultiple myelomaCement leakage
2024
Quality of Cancer Recurrence Data in the National Cancer Database: A Reappraisal of Reporting Readiness
Chan K, Palis B, Cotler J, Janczewski L, Zhu X, Boffa D, Park K, Boughey J, Plichta J, In H, Nogueira L, Yabroff R, Hawhee V, Merriman K, Habermann E, Williams V, Mason K, Mullett T, Weigel R, Nelson H. Quality of Cancer Recurrence Data in the National Cancer Database: A Reappraisal of Reporting Readiness. Annals Of Surgical Oncology 2024, 32: 1553-1564. PMID: 39739153, DOI: 10.1245/s10434-024-16801-9.Peer-Reviewed Original ResearchConceptsCancer registry staffData missingnessNational Cancer DatabaseSouthern geographic regionsMulti-method studyPhysician documentationStaff surveyData quality concernsRegistry staffNon-metastatic cancerClinical documentationOutcomes researchData abstractionInadequate documentationCancer DatabasePrimary cancerOverall low rateCancer recurrenceBackgroundThis studyNational Cancer Database analysisMissingnessRecurrence dataSurveyDocumentation of recurrenceGeographic regionsMapping extrachromosomal DNA amplifications during cancer progression
Kim H, Kim S, Wade T, Yeo E, Lipsa A, Golebiewska A, Johnson K, An S, Ko J, Nam Y, Lee H, Kang S, Chung H, Niclou S, Moon H, Paek S, Bafna V, Luebeck J, Verhaak R. Mapping extrachromosomal DNA amplifications during cancer progression. Nature Genetics 2024, 56: 2447-2454. PMID: 39402156, PMCID: PMC11549044, DOI: 10.1038/s41588-024-01949-7.Peer-Reviewed Original ResearchConceptsPretreatment tumorsCancer progressionChemotherapy-pretreated patientsNewly diagnosed tumorsVariant allele fractionUntreated metastasesPrimary cancerUntreated cancerTreatment responseFocal amplificationTumor samplesChromosomal amplificationsDiagnosed cancerTumorExtrachromosomal DNA amplificationsAdvanced cancerCancerEcDNATime pointsMetastasisNewlyDNA amplificationProgressionExtrachromosomal DNAPatientsCLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. CLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345. DOI: 10.1016/s2152-2650(24)01263-1.Peer-Reviewed Original ResearchPer-patient per-monthPer-patient per-month costsChronic lymphocytic leukemiaBruton tyrosine kinase inhibitorFirst-line treatmentTyrosine kinase inhibitorsLymphocytic leukemiaMonths 0Kinase inhibitorsHealthcare costsCLL/small lymphocytic lymphomaFixed-duration treatmentFirst-line therapyOff-treatment periodMonths post-indexMonths pre-indexRetrospective observational studyClinical trial enrollmentUS health planCommercially insured patientsLymphocytic lymphomaPrimary cancerFirst-linePost-indexIbrutinibLi-Fraumeni Syndrome: Imaging Features and Guidelines.
Gosangi B, Dixe de Oliveira Santo I, Keraliya A, Wang Y, Irugu D, Thomas R, Khandelwal A, Rubinowitz A, Bader A. Li-Fraumeni Syndrome: Imaging Features and Guidelines. RadioGraphics 2024, 44: e230202. PMID: 39024172, DOI: 10.1148/rg.230202.Peer-Reviewed Original ResearchConceptsLi-Fraumeni syndromeLifetime risk of cancerRare autosomal dominant familial cancer syndromeIncreased riskRisk of cancerTreated with total mastectomyAutosomal dominant familial cancer syndromeImaging features of tumorsFamilial cancer syndromeWhole-body MRIAnnual screeningFeatures of tumorsCancer syndromesLifetime riskP53 transcription factorLi-FraumeniAdrenocortical cancerTotal mastectomyPrimary cancerBreast malignancyImaging guidelinesBreast cancerGermline mutationsColon cancerManagement guidelinesRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failure
2022
Treatment Outcomes for Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer
Han J, Zakeri K, Raab G, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Treatment Outcomes for Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e317. DOI: 10.1016/j.ijrobp.2022.07.1381.Peer-Reviewed Original ResearchProgression-free survivalCisplatin-ineligible patientsDefinitive radiation therapyUnknown primary cancerLocoregional controlRadiation therapyDistant controlConcurrent carboplatinWeekly carboplatinAdvanced headOverall survivalHNSCC patientsPrimary cancerNeck squamous cell carcinomaConclusions Radiation therapyConsecutive HNSCC patientsCycles of chemotherapySevere ulcerative colitisUpper gastrointestinal bleedMedian radiation doseSynchronous primary malignanciesKaplan-Meier methodSquamous cell carcinomaMATERIAL/METHODSCumulative incidence functionLong-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of U.S. Health Professionals
Cheng E, Lee DH, Tamimi RM, Hankinson SE, Willett WC, Giovannucci EL, Eliassen AH, Stampfer MJ, Mucci LA, Fuchs CS, Spiegelman D. Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of U.S. Health Professionals. JNCI Cancer Spectrum 2022, 6: pkac021-. PMID: 35603853, PMCID: PMC8973409, DOI: 10.1093/jncics/pkac021.Peer-Reviewed Original ResearchConceptsCancer-specific mortalityHealth Study IIUterine corpusCause of deathCommon cancerThyroid cancerPrimary cancerCancer survivorsLung cancerCumulative mortalityHealth StudyColorectal cancer-specific mortalityLong-term overall survivalNurses' Health Study IICancer-specific mortality ratesU.S. health professionalsHealth Professionals FollowNurses' Health StudyMale cancer survivorsFemale cancer survivorsProfessionals FollowMost patientsOverall survivalExcess riskUrinary bladderEvent-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal Of Medicine 2022, 386: 556-567. PMID: 35139274, DOI: 10.1056/nejmoa2112651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleHumansIntention to Treat AnalysisKaplan-Meier EstimateMiddle AgedNeoadjuvant TherapyProgression-Free SurvivalTriple Negative Breast NeoplasmsConceptsEarly triple-negative breast cancerTriple-negative breast cancerEvent-free survivalCycles of pembrolizumabPathological complete responseDefinitive surgeryBreast cancerNeoadjuvant chemotherapyComplete responseLonger event-free survivalUntreated stage IIPrimary end pointPhase 3 trialSecond primary cancerDoxorubicin-cyclophosphamideNeoadjuvant pembrolizumabNeoadjuvant phaseAdjuvant therapyDistant recurrenceNeoadjuvant therapyAdverse eventsPrimary cancerSafety profileDisease progressionPembrolizumab
2021
Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Yu J, Tsay C, Sasaki C, Son YH, Decker RH, Mehra S, Burtness B. Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. Oral Oncology 2021, 122: 105585. PMID: 34688055, DOI: 10.1016/j.oraloncology.2021.105585.Peer-Reviewed Original ResearchConceptsNon-cancer mortalitySecond primary cancerExternal beam radiationOPC patientsPrimary cancerOral cavityHigher cancer-specific mortalityOropharyngeal squamous cell cancerBrachytherapy-treated patientsElectronic medical record dataImpact of brachytherapyInstitutional tumor registryCancer-specific mortalitySquamous cell cancerProportional hazards regressionCause of deathMedical record dataBeam radiationEligible patientsMortality HROropharynx SCCPrimary malignancySmoking historyPrimary outcomeTreatment regimenUpdated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal Of Clinical Oncology 2021, 39: 2720-2731. PMID: 34003702, PMCID: PMC10166345, DOI: 10.1200/jco.20.03613.Peer-Reviewed Original ResearchConceptsEfficacy end pointPrimary end pointBreast cancer clinical trialsPrimary cancerCancer clinical trialsEnd pointStandardized definitionsRecurrence rateClinical trialsInvasive disease-free survival eventsTherapy trialsBreast cancer-free survivalDisease-free survival eventsNon-breast cancer deathPrimary efficacy end pointClinical trial end pointsPhase III breast cancer trialsCancer-free survivalSecond primary cancerTrial end pointsAdditional end pointsBreast cancer trialsLow-risk populationPatient-reported outcomesSurvival end points
2020
The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization.
Wong W, Sheinson D, Ogale S, Flores C, Gross C. The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization. Journal Of Clinical Oncology 2020, 38: 98-98. DOI: 10.1200/jco.2020.38.29_suppl.98.Peer-Reviewed Original ResearchMetastatic breast cancerMetastatic colorectal cancerAdvanced non-small cell lung cancerNational coverage decisionNGS testingUtilization trendsNext-generation sequencingNGS testsNon-small cell lung cancerCell lung cancerInterrupted time series analysisDe-identified databaseDiagnosis dateAdvanced melanomaPrimary cancerRetrospective studyColorectal cancerLung cancerInsurance typeCancer clinicMetastatic cancerBreast cancerUse of NGSTesting ratesCancerNationwide Patterns of Pathologic Fractures Among Patients Hospitalized With Bone Metastases
Jairam V, Lee V, Yu JB, Park HS. Nationwide Patterns of Pathologic Fractures Among Patients Hospitalized With Bone Metastases. American Journal Of Clinical Oncology 2020, 43: 720-726. PMID: 32694296, DOI: 10.1097/coc.0000000000000737.Peer-Reviewed Original ResearchConceptsPathologic fractureBone metastasesMultiple myelomaUtilization Project National Inpatient SampleLonger inpatient staysMultivariable logistic regressionNational Inpatient SampleIntrahepatic bile ductsRenal pelvis cancerRenal cell carcinomaProphylactic stabilizationHospital admissionPrimary cancerBile ductInpatient stayPelvis cancerCell carcinomaInpatient SamplePrimary diagnosisRisk factorsBaseline differencesOutpatient monitoringHigh riskHealthcare costsPatientsDiagnostic Value of CT of Chest, Abdomen, and Pelvis in Patients With Solitary and Multiple Brain Lesions.
Rothman RK, Weinreb J, Zucconi W, Malhotra A. Diagnostic Value of CT of Chest, Abdomen, and Pelvis in Patients With Solitary and Multiple Brain Lesions. American Journal Of Roentgenology 2020, 214: 636-640. PMID: 31939701, DOI: 10.2214/ajr.19.22051.Peer-Reviewed Original ResearchConceptsPrimary neoplasmsBrain lesionsChest CTIntracranial lesionsCT CAPAncillary signsBrain neoplasmsNew intracranial lesionsPrimary brain neoplasmsMultiple brain lesionsMalignant brain neoplasmsLarge academic hospitalPresence of enhancementBrain metastasesLung primaryMetastatic workupSuch patientsPrimary cancerLesion characteristicsAcademic hospitalBenign entityCT scanPatientsMalignant casesNeoplasms
2019
LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY
Williams N, Rinehardt H, Morgan E, Kassem M, Palettas M, Puduvalli V, Giglo P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY. Neuro-Oncology Advances 2019, 1: i8-i8. PMCID: PMC7213376, DOI: 10.1093/noajnl/vdz014.033.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalPrimary cancerOhio State University Comprehensive Cancer CenterSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologySolid tumor malignanciesConfirmation of diagnosisComprehensive cancer centerClinical characteristicsMedian ageMRI findingsInitial diagnosisQuality Versus Quantity
Chiu AS, Arnold BN, Hoag JR, Herrin J, Kim CH, Salazar MC, Monsalve AF, Jean RA, Blasberg JD, Detterbeck FC, Gross CP, Boffa DJ. Quality Versus Quantity. Annals Of Surgery 2019, Publish Ahead of Print: &na;. PMID: 29697446, DOI: 10.1097/sla.0000000000002762.Peer-Reviewed Original ResearchConceptsComplex cancer surgeryCancer surgerySafe hospitalComplex oncologic surgeryPotential mortality reductionNational Cancer DatabaseHigh-volume hospitalsHospital quality measuresSurgical mortalityPrimary cancerHospital rating systemsOncologic surgeryCancer DatabaseMortality reductionSurgical volumeHospital safetyPatient realignmentPatientsHospitalSurgeryMeaningful reductionPublic reportingMortalityRSMRCancerAssessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.
Rinehardt H, Morgan E, Kassem M, Palettas M, Miah A, Alnahhas I, Guillermo Prieto Eibl P, Suresh A, Ganju A, Williams N, Puduvalli V, Giglio P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University. Journal Of Clinical Oncology 2019, 37: e13554-e13554. DOI: 10.1200/jco.2019.37.15_suppl.e13554.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalMRI findingsPrimary cancerLung cancerBreast cancerOhio State University Comprehensive Cancer CenterStage IV breast cancerSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseHigh-risk patientsKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologyConfirmation of diagnosisComprehensive cancer centerEmergency department visits for prescription and synthetic opioid overdoses among patients with cancer.
Jairam V, Yang D, Yu J, Park H. Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer. Journal Of Clinical Oncology 2019, 37: 6579-6579. DOI: 10.1200/jco.2019.37.15_suppl.6579.Peer-Reviewed Original ResearchED visitsOpioid overdoseEmergency departmentHigh riskOverdose ratesCervical cancerSynthetic opioidsUtilization Project Nationwide Emergency Department SampleNationwide Emergency Department SampleNon-cancer patientsEnd Results ProgramEmergency Department SampleIntrahepatic bile ductsPrimary cancer siteSynthetic opioid overdoseDiagnosis of cancerRespiratory intubationMetastatic diseaseHospital admissionOpioid dependencePrimary cancerBile ductResults ProgramCancer patientsCommon cancerFactors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.
Leone J, Vallejo C, Hassett M, Leone J, Freedman R, Tolaney S, Leone B, Lin N, Winer E. Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal Of Clinical Oncology 2019, 37: 540-540. DOI: 10.1200/jco.2019.37.15_suppl.540.Peer-Reviewed Original ResearchRisk of BCSMBreast cancer-specific mortalityHR- breast cancerBreast cancerAdjusted riskCumulative riskAnnual event rateCancer-specific mortalityHormone receptor statusBreast cancer deathsEnd Results registryBetter adjuvant therapyKaplan-Meier analysisLong-term riskLate deathsAdjuvant therapyLate relapseReceptor statusHR statusPrimary cancerCox regressionBaseline variablesBlack raceCancer deathClinical trials
2018
Coexistence of medullary thyroid carcinoma and recurrent non-functional pituitary adenoma: a case report
Bagherzadeh M, Aminorroaya A, Vafaeimanesh J, Mohajeri-Tehrani M. Coexistence of medullary thyroid carcinoma and recurrent non-functional pituitary adenoma: a case report. Journal Of Medical Case Reports 2018, 12: 220. PMID: 30107852, PMCID: PMC6092822, DOI: 10.1186/s13256-018-1745-5.Peer-Reviewed Original ResearchConceptsMedullary thyroid carcinomaRecurrent non-functioning pituitary adenomaNon-functioning pituitary adenomasPituitary adenomasThyroid carcinomaPrimary cancerCoexistence of medullary thyroid carcinomaTumor-to-tumor metastasis phenomenonNon-functioning pituitary macroadenomaChief complaint of headacheBackgroundMedullary thyroid carcinomaMultiple endocrine neoplasia syndromeParafollicular C cellsSecond primary cancersSurgery several yearsComplaints of headacheEndocrine neoplasia syndromeTranssphenoidal surgeryPituitary macroadenomaNeuroendocrine tumorsPrimary neoplasmsBenign hyperplasiaNeoplasia syndromeChief complaintSymptom-free
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply